Please use this identifier to cite or link to this item:
|Title:||Hepatitis C recurrence: the Achilles heel of liver transplantation.|
|Authors:||Howell, Jessica;Angus, Peter W;Gow, Paul J|
|Affiliation:||Liver Transplant Unit, Austin Hospital, Melbourne, Australia; Department of Medicine, University of Melbourne, Melbourne, Australia.|
|Citation:||Transplant Infectious Disease : An Official Journal of the Transplantation Society 2013; 16(1): 1-16|
|Abstract:||Hepatitis C virus (HCV) infection is the most common indication for liver transplantation worldwide; however, recurrence post transplant is almost universal and follows an accelerated course. Around 30% of patients develop aggressive HCV recurrence, leading to rapid fibrosis progression (RFP) and culminating in liver failure and either death or retransplantation. Despite many advances in our knowledge of clinical risks for HCV RFP, we are still unable to accurately predict those most at risk of adverse outcomes, and no clear consensus exists on the best approach to management. This review presents a critical overview of clinical factors shown to influence the course of HCV recurrence post transplant, with particular focus on recent data identifying the important role of metabolic factors, such as insulin resistance, in HCV recurrence. Emerging data for genetic markers of HCV recurrence and their usefulness for predicting adverse outcomes will also be explored.|
|Internal ID Number:||24372756|
living donor transplantation
Hepatitis C, Chronic
Metabolic Syndrome X
Reoperation.statistics & numerical data
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.